Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most grapefruit/food-interaction claims are partially supported (grapefruit juice increases atorvastatin plasma concentrations), but several claims extend beyond the label excerpts provided (e.g., snack-label screening, alcohol/heavy snack pairings and liver strain, and effectiveness/side-effect-risk conclusions framed broadly).
Category Scores
Accurate Statements
Grapefruit juice contains components that inhibit CYP3A4 and can increase plasma concentrations of atorvastatin (especially with excessive grapefruit juice consumption).
Label Section 7.2 (Grapefruit Juice): inhibits CYP 3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (>1.2 liters per day).
Food can decrease the rate and extent of drug absorption.
Label Section 12.3 (Pharmacokinetics—food timing and absorption): food decreases rate and extent of drug absorption.
Food does not necessarily change LDL-C reduction when given with or without food.
Label Section 12.3: LDL-C reduction is similar whether LIPITOR is given with or without food.
Unsupported Statements
Lipitor (atorvastatin) level in the body depends partly on how it is absorbed in the gut and how it is processed by liver enzymes and transporters.
Label excerpts provided mention food affecting absorption rate/extent (Section 12.3) and metabolism via CYP3A4 (Section 7.1), but do not support the specific combined claim about 'liver enzymes and transporters' governing levels.
Grapefruit can affect intestinal enzymes and transporters that metabolize drugs like atorvastatin.
Label Section 7.2 attributes grapefruit effect to CYP3A4 inhibition and increased plasma concentrations; it does not mention intestinal enzymes/transporters.
Grapefruit can change the amount of atorvastatin absorbed.
The provided label excerpt supports increased plasma concentrations with grapefruit juice (Section 7.2) but does not explicitly state grapefruit changes absorption.
Grapefruit may reduce Lipitor’s effectiveness.
Label excerpt does not state grapefruit reduces effectiveness; Section 12.3 says LDL-C reduction is similar with/without food, but no comparable statement is provided for grapefruit.
Grapefruit may increase side effects risk for some people.
Label excerpts provided describe increased plasma concentrations with grapefruit juice (Section 7.2) and general myopathy risk with certain drugs (Section 7 intro/Section 5), but do not explicitly connect grapefruit to increased side-effect risk.
Snack items that contain or are made with ingredients known to affect drug metabolism are the main concern for interfering with atorvastatin.
Label excerpts do not discuss snacks or generalize 'main concern' to snack ingredients.
Other citrus components besides grapefruit may affect drug-handling enzymes.
No label excerpt provided supports effects of citrus components other than grapefruit.
Alcohol-heavy snack pairings are relevant because statins are metabolized in the liver, and this may involve liver strain.
Label excerpts provided do not discuss alcohol interactions or alcohol-related liver strain in the context of atorvastatin.
If a snack label lists grapefruit, grapefruit juice, or grapefruit-derived ingredients, it should be treated as potentially interacting with Lipitor.
Label excerpt specifically addresses grapefruit juice and excess consumption (>1.2 liters/day); it does not provide guidance about snack labels or grapefruit-derived ingredients generally.
The safest approach is to avoid grapefruit while taking Lipitor unless a clinician says otherwise.
Label excerpt supports grapefruit juice increasing plasma concentrations (Section 7.2) but does not explicitly recommend avoiding grapefruit generally or provide the 'unless clinician says otherwise' phrasing.
Patients should avoid grapefruit and grapefruit-derived products unless their prescriber approves them.
No explicit 'avoid grapefruit' or prescriber-approval wording is present in the provided grapefruit interaction excerpt.
Patients should check snack labels for grapefruit ingredients or grapefruit juice concentrate.
Label excerpt does not provide label-checking instructions.
Contradictions
Important Omissions
The label excerpt provides specificity that grapefruit interaction is linked to CYP3A4 inhibition and increased plasma concentrations, 'especially with excessive grapefruit juice consumption (>1.2 liters per day)'. The AI statements did not include this threshold/level of excess.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Some claims over-generalize beyond the provided label excerpt (e.g., broad effectiveness/side-effect risk and avoidance/label-instruction guidance), though the core interaction concept that grapefruit juice can increase atorvastatin plasma concentrations is supported.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Over-generalization and unsupported guidance (e.g., broad avoidance of grapefruit, snack-label and grapefruit-derived ingredient recommendations, and alcohol/heavy snack liver-strain rationale) not explicitly supported by the provided label excerpts.
Suggested Improvement
Align claims to the label excerpt for grapefruit juice: specify CYP3A4 inhibition and increased plasma concentrations, particularly with excessive grapefruit juice consumption (>1.2 liters/day), and avoid adding snack/alcohol guidance or broad 'reduced effectiveness/increased side effects risk' conclusions unless supported by the full label.